Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Exelixis gains $12m upfront in Merck PI3K-delta deal

This article was originally published in Scrip

Executive Summary

Exelixis has granted Merck & Co exclusive, worldwide rights to its preclinical PI3K-delta R&D programme – giving the biotech cancer developer the resources to move forward on its high-stakes late-stage development programme for lead compound carbozantinib, a potential treatment for medullary thyroid and prostate cancers.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC015672

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel